A new study has revealed that GLP-1 drugs, commonly used for diabetes and weight loss, show promise in treating alcohol addiction. The research, published in JAMA Psychiatry, found that semaglutide and liraglutide may reduce alcohol cravings by influencing the brain's reward system.

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at curbing alcohol abuse.

The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require hospitalization, new research shows. Numerous studies had already hinted that semaglutide might act on appetite centers in the brain to suppress the urge to drink,

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests.

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published Wednesday in JAMA Psychiatry said. The study examined about 228,000 people in Sweden who had alcohol use disorder and Type 2 diabetes.

Another day, another study linking Ozempic to major health benefits. Published Wednesday in JAMA Psychiatry, the study found that patients diagnosed with alcohol use disorder (AUD) who were given a GLP-1 drug were less likely to be hospitalized for alcohol-related issues.